 RESEARCH TRIANGLE PARK, N.C., July 29, 2020 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET. The live call may be accessed by dialing 866-763-6020 domestic or 210-874-7713 international and entering the conference code: 4648036. The live and archived webcast will be available on the Events Presentations page of the G1 website.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader SERD for the treatment of ER breast cancer. Lerociclib is a differentiated oral CDK46 inhibitor designed to enable more effective combination treatment strategies.G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter G1Therapeutics.Contact: Jeff Macdonald Senior Director, Investor Relations Corporate Communications 919-907-1944 